We have assembled a team of highly competent and dedicated individuals from the worlds of science and business who believe strongly in the potential of our technology to propel Calando Pharmaceuticals to new levels of success. The following management groups guide our internal scientific team and a cadre of internationally recognized consultants and advisors.
| EXECUTIVE MANAGEMENT TEAM |
 |
|
Christopher Anzalone, Ph.D., Chief Executive Officer. Dr. Anzalone is also the CEO of Arrowhead Research Corporation. Prior to his involvement with Arrowhead, Dr Anzalone was CEO and founder of the Benet Group, a private equity firm focused on creating and building new nanobiotechnology companies from university-generated science. Prior to Benet, Dr. Anzalone was a partner at the Washington DC-based private equity firm Galway Partners, LLC. There, he was in charge of sourcing, structuring, and building new business ventures and was founding CEO of NanoInk, Inc., a leading nanolithography company. Dr. Anzalone holds a Ph.D. and M.A. in Biology from UCLA and a B.A. in Government from Lawrence University.
|
 |
|
Thomas Schluep, Sc.D., Chief Scientific Officer is an expert in translating delivery system and therapy innovations into pharmaceutical and biotech product candidates. Prior to the merger of Calando with Insert Therapeutics, Dr. Schluep was the Chief Scientific Officer of Insert Therapeutics, where he headed drug discovery and development programs for the polymeric delivery system Cyclosert and the IT-101 candidate. While at Insert he drove the novel polymer-based cancer drug, IT-101, from laboratory to Phase I clinical trial in < 2 years. Prior to joining Insert, he was responsible for the non-viral gene therapy program at Canji, Inc., a wholly owned subsidiary of Schering-Plough. He successfully led an interdisciplinary team of scientists in their effort to develop synthetic gene delivery vehicles for the systemic treatment of cancer with the p53 tumor suppressor gene. Prior to Canji, Dr. Schluep was a post-doctoral associate at the department of Chemical Engineering at the Massachusetts Institute of Technology. He received his Sc.D. in Process Engineering in 1995 and an MS in Biotechnology in 1989, both from the Swiss Federal Institute of Technology in Zurich, Switzerland. |
 |
|
Jeremy Heidel, Consultant
– Oligonucleotide delivery , earned his bachelor’s degrees in Chemical Engineering and Biology from MIT and his M.S. and Ph.D. degrees in Chemical Engineering from Caltech. Dr. Heidel performed his doctoral thesis research on targeted, systemic, non-viral delivery of siRNA in the laboratory of Dr. Mark Davis, and has expertise in the areas of: (i) synthesis and characterization of polymeric delivery vehicles and their formulations, (ii) identification of siRNA target sites and the design of potent RNAi molecules, and (iii) the design and execution of in vitro and in vivo experiments to evaluate formulation efficacy. He was the first to show that synthetic siRNA molecules do not elicit immune responses in animals. |
| BOARD OF DIRECTORS |
| |
|
The members of Calando’s Board are:
Christopher Anzalone, Ph.D. CEO, serves as chairman of the Board and director.
R. Bruce Stewart is Executive Chairman of Arrowhead Research Corporation. Prior to his involvement with Arrowhead, from March 1991 to January 1997, as the founder of Acacia Research Corporation, he served as its Chairman and President. From August 1977 to March 1991, Mr. Stewart was the President of Annandale Corporation. He also was a licensed principal of Annandale Securities, Inc., a licensed broker -dealer.
Edward W. Frykman retired from his position as an Account Executive with Crowell, Weedon & Co. since 1992. Previously, Mr. Frykman served as Senior Vice President of L.H. Friend & Co. Both Crowell, Weedon & Co. and L.H. Friend & Co. are investment brokerage firms located in Southern California. In addition, Mr. Frykman was a Senior Account Executive with Shearson Lehman Hutton where he served as the Manager of the Los Angeles Regional Retail Office of E. F. Hutton & Co. Mr. Frykman is also a director of Arrowhead Research Corporation. |
